Adult T-cell leukemia (ATL) is a rare but aggressive CD4 + CD25 + leukemia triggered by HTLV-1 infection. We quantified ex vivo levels of CD4 + and CD8 + (sub)populations and their antiproliferative, pro-apoptotic, antiviral and immunomodulatory interplay in short-term culture of primary cells from ATL patients, in a long-term prospective study (819 person-years of follow-up). We integrated clinical, cellular and molecular data into a data mining approach combining linear (consensus HI erarchical T ree clustering) and non-linear ( BAY esian network) models. This HIT-BAY approach revealed an association between CD8 + CD25 + cells and survival, independent of CD4 + CD25 + cells. Moreover, CD8 + CD25 + levels at diagnosis significantly predicted 5-year survival in ATL patients (p=0.037), which was confirmed in multivariable Cox regression models correcting for clinical forms. We provide in vivo support for our ex vivo model in a unique patient on AZT monotherapy, for whom adding IFN-α resulted in a rapid (<2 weeks) and pronounced (>70%) decline in leukemic/non-leukemic cell ratio, accompanied by a ten-fold increase CD8 + CD25 + levels, and followed by long-term survival. Finally, transcriptomic analysis of a CD8 + CD25 + gene module and replication in an independent ATL cohort revealed shared cytotoxic activity of both CD8+CD25+ and Tax-specific CD8+ cells as an underlying mechanism for prolonged survival. In conclusion, our integrated data mining approach allowed us to integrate ex vivo clinical and immunological data, revealing a central role for CD8+CD25+ cells in ATL survival. HIT-BAY might serve as a prototype to model immune response and facilitate biomarker and therapeutic target discovery in real-world cohorts, including rare malignancies.
No takes yet. Share an insight, caveat, or question.
Khouri et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: